Craig-Hallum Remains a Buy on ScPharmaceuticals (SCPH)

TipRanksApr 25 21:15

ScPharmaceuticals Enrolls First Participant In Pivotal Pharmacokinetic Study Of FUROSCIX Auto-Injector Injection

FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body InfusorCompany anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 20

BenzingaApr 24 20:01

12 Health Care Stocks Moving In Friday's Pre-Market Session

GainersProtara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (N

BenzingaApr 5 20:09

Buy Rating Affirmed for ScPharmaceuticals Amidst Revenue Surge and Solid Financial Footing

TipRanksMar 15 19:25

HC Wainwright & Co. Reiterates Buy on ScPharmaceuticals, Maintains $18 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates scPharmaceuticals with a Buy and maintains $18 price target.

Analyst UpgradesMar 14 19:23

ScPharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/14/2024 229.07% HC Wainwright & Co. → $18 Reiterates Buy → Buy 09/07/2023 265.63% Craig-Hallum → $20 In

BenzingaMar 14 19:22